The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD

The design and improvement of a novel series of muscarinic M3 receptor antagonists is described, leading to the identification of AZD8683, which was selected for clinical evaluation as a potential treatment for COPD.